Results 111 to 120 of about 52,122 (312)

The opioid crisis: past, present and future policy climate in Ontario, Canada

Substance Abuse Treatment, Prevention, and Policy, 2017
Background Addressing opioid use disorder has become a priority in Ontario, Canada, because of its high economic, social and health burden. There continues to be stigma and criticism relating to opioid use disorder and treatment options.
Kristen A. Morin, Joseph K. Eibl, Alexandra M. Franklyn, David C. Marsh   +3 more
doaj   +1 more source

Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series

Addiction, EarlyView.
Abstract Background and aims Evidence regarding the impacts of supervised drug consumption services (SDC) remains mixed, and few evaluations have used individual‐level, linkable health data to examine service withdrawal. In September 2024, the Red Deer overdose prevention site (OPS) in Alberta, Canada, was scheduled for closure, with operations ceasing
Nathaniel Day, Kym Kaufmann, Daniel John Alexander Devoe, Vanja Grubac, Alessia DiMarzo, Haisa Osmanli, Vanessa Norton, Shelly Vik, Nickie Mathew, Robert Lawrence Tanguay, Anees Bahji   +10 more
wiley   +1 more source

RELATIVE POTENCY OF AGONIST AND PARTIAL AGONIST OPIOIDS

British Journal of Anaesthesia, 1985
M.D. VICKERS, M. ROSEN
openaire   +3 more sources

Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain – A Review of Current Evidence

Journal of Pain Research, 2021
Hon Sen Tan,1 Ashraf S Habib2 1Department of Women’s Anesthesia, KK Women’s and Children’s Hospital, 229899, Singapore; 2Department of Anesthesiology, Division of Women’s Anesthesia, Duke University Medical Center, Durham, NC ...
Tan HS, Habib AS
doaj  

Logistic regression estimates for receipt of opioid agonist therapy for opioid use disorder among admitted patients, 2014–17.

, 2019
Logistic regression estimates for receipt of opioid agonist therapy for opioid use disorder among admitted patients, 2014–17.
Justin C. Yang (6882941), Carol Brayne (17434), Andres Roman-Urrestarazu (5447288)   +2 more
core   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Nociceptin/orphanin FQ – NOP receptor system: novel genetic and pharmacological tools

, 2012
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. In cells expressing the NOP receptor N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Molinari, Stefano
core  

Drug sellers' use of a drug checking service amid the overdose crisis in British Columbia, Canada

Addiction, EarlyView.
Abstract Aims This study examined the use of a drug checking service by drug sellers in British Columbia, Canada, to assess motivations for service use and substances intended for distribution, focusing on risks associated with an unstable illicit drug market.
Pablo Gonzalez‐Nieto, Bruce Wallace, Collin Kielty, Irene Shkolnikov, Ava Margolese, Jaime Arredondo Sanchez Lira, Chris Gill, Dennis Hore   +7 more
wiley   +1 more source

Agonist activity of N-desmethylclozapine at delta-opioid receptors of human frontal cortex

, 2009
The clozapine metabolite N-desmethylclozapine (NDMC) has been recently shown to act at different neurotransmitter receptors and to display both antagonist and agonist activities.
DEDONI, SIMONA, ONALI, PIER LUIGI, AMBU, ROSSANO, OLIANAS, MARIA CONCETTA   +3 more
core   +1 more source